ALTSGEYMER KASALLIGIDA QO’LLANILADIGAN XOLINESTERAZA INGIBITORLARINING FARMAKODINAMIK XUSUSIYATLARI
Keywords:
demensiya, beta-amiloid, tau oqsili, xolinesteraza ingibitorlari, memantinAbstract
Altsgeymer kasalligi — progressiv neyrodegenerativ kasallik bo‘lib, kognitiv funksiyalarning asta-sekin pasayishi bilan xarakterlanadi. Kasallik asosan keksa yoshdagi aholida uchraydi va demensiyaning eng keng tarqalgan sababidir. Ushbu maqolada Altsgeymer kasalligining etiopatogenezi, klinik belgilari, zamonaviy diagnostika usullari hamda farmakologik davolash prinsiplari tahlil qilindi. Zamonaviy davolash usullari kasallikni to‘liq davolamaydi, ammo simptomatik yengillik beradi va kasallik progresini sekinlashtiradi.
References
1.Alzheimer’s Association. Alzheimer’s disease facts and figures. Alzheimer’s & Dementia. 2023.
2. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer’s disease. Science. 2002;297:353–356.
3. Goedert M., Spillantini M.G. Tau pathology in neurodegenerative diseases. Lancet Neurology. 2006;5:235–245.
4. Dauer W., Przedborski S. Parkinson’s disease: mechanisms and models. Neuron. 2003;39:889–909.
5. Schapira A.H.V. Mitochondrial dysfunction in Parkinson’s disease. Lancet Neurology. 2008;7:97–109.
6. Heneka M.T., et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurology. 2015;14:388–405.
